Search results
486. 2010. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. GL Verdine, LD Walensky. Clinical cancer research 13 (24), 7264-7270. , 2007. 475. 2007. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Loren D. Walensky. Loren David Walensky is an American physician-scientist and pediatric oncologist at the Dana–Farber Cancer Institute since 2003 and a professor of pediatrics at the Dana–Farber/Harvard Cancer Center. He researches peptides and oncogenic pathways. In 2013, Walensky became director of the joint MD/PhD program at Harvard ...
- 3
- .mw-parser-output .marriage-line-margin2px{line-height:0;margin-bottom:-2px}.mw-parser-output .marriage-line-margin3px{line-height:0;margin-bottom:-3px}.mw-parser-output .marriage-display-ws{display:inline;white-space:nowrap}, Rochelle Walensky (m. 1995)
Loren D. Walensky, MD, PhD . Physician ; Principal Investigator, Linde Program in Cancer Chemical Biology ; Professor of Pediatrics, Harvard Medical School ; Appointment Phone. 888-733-4662 (New Pediatric Patients) 617-632-3270 (Established Pediatric Patients) Fax. 617-582-8240
25 Shattuck Street Boston, MA 02115 CSS Styles Code. fcf2c6b74fbdd7d4cf432a1c39a278f0
Aug 23, 2012 · Loren D Walensky is an Associate Professor of Pediatrics at Harvard Medical School, faculty member in the Department of Pediatric Hematology/Oncology at Dana-Farber Cancer Institute/Children’s Hospital Boston, and Medical Director of Dana-Farber’s Program in Cancer Chemical Biology. He graduated as valedictorian from Princeton University in ...
May 1, 2019 · Professor of Pediatrics. 617-355-6369. Email. Publications. Publications View. Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. Authors: Authors: Mourtada R, Herce HD, Yin DJ, Moroco JA, Wales TE, Engen JR, Walensky LD. Nat Biotechnol 2019-10-01.
Loren D. Walensky, MD, PhD. Dr. Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in pediatrics, completed a fellowship in pediatric hematology-oncology at Dana-Farber and Boston Children's Hospital, and is board-certified in pediatric ...
